These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31482335)

  • 21. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data.
    Scotcher D; Jones C; Posada M; Rostami-Hodjegan A; Galetin A
    AAPS J; 2016 Sep; 18(5):1067-1081. PubMed ID: 27365096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.
    Fan J; Chen S; Chow EC; Pang KS
    Curr Drug Metab; 2010 Nov; 11(9):743-61. PubMed ID: 21189137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of drug transporters on volume of distribution.
    Grover A; Benet LZ
    AAPS J; 2009 Jun; 11(2):250-61. PubMed ID: 19399628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical review of pharmacology concepts.
    Janda SM; Fagan NL
    Urol Nurs; 2010; 30(1):15-20. PubMed ID: 20359141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Kidney and drugs - urinary lithiasis. Pharmacokinetic glossary].
    Balant L
    Rev Med Suisse Romande; 1980 Nov; 100(11):949-56. PubMed ID: 7466067
    [No Abstract]   [Full Text] [Related]  

  • 26. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
    Momper JD; Tsunoda SM; Ma JD
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S82-98. PubMed ID: 27385182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
    Feng B; Varma MV; Costales C; Zhang H; Tremaine L
    Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps.
    Okudaira N
    J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.
    Rodieux F; Gotta V; Pfister M; van den Anker JN
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S173-92. PubMed ID: 27385174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses.
    Benet LZ; Bowman CM; Liu S; Sodhi JK
    Pharm Res; 2018 Oct; 35(12):242. PubMed ID: 30349948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An estimation method of the clearance for a one-compartment model of a single bolus intravenous injection by a single sampling.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2012; 22(1):43-53. PubMed ID: 22204526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.
    El-Kattan AF; Varma MVS
    Drug Metab Dispos; 2018 May; 46(5):729-739. PubMed ID: 29496721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters.
    Berezhkovskiy LM
    J Pharm Sci; 2009 Feb; 98(2):748-62. PubMed ID: 18506769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.
    Pan Y; Hsu V; Grimstein M; Zhang L; Arya V; Sinha V; Grillo JA; Zhao P
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S122-31. PubMed ID: 27385170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance (née Rowland) concepts: a downdate and an update.
    Benet LZ
    J Pharmacokinet Pharmacodyn; 2010 Dec; 37(6):529-39. PubMed ID: 21113650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.
    Kimoto E; Obach RS; Varma MVS
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):18-29. PubMed ID: 31952912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transporters as a determinant of drug clearance and tissue distribution.
    Shitara Y; Horie T; Sugiyama Y
    Eur J Pharm Sci; 2006 Apr; 27(5):425-46. PubMed ID: 16488580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds.
    Lombardo F; Berellini G; Obach RS
    Drug Metab Dispos; 2018 Nov; 46(11):1466-1477. PubMed ID: 30115648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues.
    Tourancheau A; Rouleau M; Guauque-Olarte S; Villeneuve L; Gilbert I; Droit A; Guillemette C
    Pharmacogenomics J; 2018 Apr; 18(2):251-261. PubMed ID: 28440341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.